SkinBioTherapeutics (LSE:SBTX) ROE % Adjusted to Book Value: -3.59% (As of Dec. 2025)


LSE:SBTX SkinBioTherapeutics PLC LSE:SBTX
40 GF Score
Price £0.11
GF Value £0.64
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SkinBioTherapeutics ROE % Adjusted to Book Value?

SkinBioTherapeutics LSE:SBTX 40 ROE % Adjusted to Book Value is -3.59% as of Dec. 2025. GuruFocus rates LSE:SBTX with a GF Score™ of 40/100 and a GF Value™ of £0.64 (Possible Value Trap). The stock has 3 warning signs investors should review.

SkinBioTherapeutics's ROE % for the quarter that ended in Dec. 2025 was -18.26%. SkinBioTherapeutics's PB Ratio for the quarter that ended in Dec. 2025 was 5.08. SkinBioTherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -3.59%.

SkinBioTherapeutics ROE % Adjusted to Book Value Related Terms

SkinBioTherapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for SkinBioTherapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SkinBioTherapeutics ROE % Adjusted to Book Value Chart

SkinBioTherapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.94 -5.74 -12.17 -19.87 -2.41

SkinBioTherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.78 -15.97 -6.00 2.08 -3.59

LSE:SBTX vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, SkinBioTherapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SkinBioTherapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SkinBioTherapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where SkinBioTherapeutics's ROE % Adjusted to Book Value falls into.


LSE:SBTX
40GF Score
SkinBioTherapeutics PLC LSE:SBTX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SkinBioTherapeutics ROE % Adjusted to Book Value Calculation

SkinBioTherapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-11.24% / 4.67
=-2.41%

SkinBioTherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-18.26% / 5.08
=-3.59%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -3.59% mean?
SkinBioTherapeutics (LSE:SBTX) has a ROE % Adjusted to Book Value of -3.59% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on SkinBioTherapeutics and its competitors.
Is SkinBioTherapeutics' ROE % Adjusted to Book Value too high?
SkinBioTherapeutics' current ROE % Adjusted to Book Value is -3.59%. Overall, SkinBioTherapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SkinBioTherapeutics' ROE % Adjusted to Book Value compare to VRTX and REGN?
SkinBioTherapeutics' ROE % Adjusted to Book Value of -3.59% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on SkinBioTherapeutics and its competitors. SkinBioTherapeutics's current ROE % Adjusted to Book Value is -3.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SkinBioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, SkinBioTherapeutics (LSE:SBTX) is currently considered Possible Value Trap. The stock's GF Value™ is £0.64, compared to a current price of £0.11 — trading 83.6% below its estimated fair value. The current ROE % Adjusted to Book Value is -3.59%. SkinBioTherapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For SkinBioTherapeutics (LSE:SBTX), the current ROE % Adjusted to Book Value is -3.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SkinBioTherapeutics (LSE:SBTX) Overvalued in 2026?

Based on GuruFocus' analysis, SkinBioTherapeutics stock appears to be undervalued. The current stock price of £0.11 is trading 83.6% below its estimated GF Value™ of £0.64. GuruFocus considers SkinBioTherapeutics to be Possible Value Trap.

Key valuation signals for LSE:SBTX:

  • ROE % Adjusted to Book Value: -3.59%
  • GF Value™: £0.64 vs. price of £0.11 (83.6% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the LSE:SBTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SkinBioTherapeutics Business Description

Address Bath Lane, The Core, Newcastle Helix, Newcastle upon Tyne, GBR, NE4 5TF
SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
40GF Score

Get the complete analysis for LSE:SBTX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.11
Price
£0.64
GF Value